---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-148822"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T18:36:52.888384+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cortexyme to merge with Novosteo; to issue ~6M shares, appoints Novosteo CEO as CEO

## Summary
- Enters definitive agreement to acquire Novosteo via reverse merger; expects to issue ~6M shares in transaction.
- Post-merger pro forma cash, cash equivalents and investments of ~$120M as of March 31, 2022.
- Dirk Thye, MD (Novosteo CEO) to become Cortexyme CEO; Chris Lowe steps down as interim CEO but remains CFO/COO.
- Philip Low, PhD appointed to Cortexyme board; independent board approves 4,000,000-share inducement plan for new hires.
- Closing expected within 30 days, subject to Novosteo stockholder approval and other customary conditions.

## SEC filing metadata
- accession: 0001193125-22-148822
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 3.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312522148822/0001193125-22-148822-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312522148822/d316217d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-148822
- JSON: https://secwatch.observer/filing/0001193125-22-148822.json
- Plain text: https://secwatch.observer/filing/0001193125-22-148822.txt

## Key facts
- Executive change
  Dirk Thye was appointed as Chief Executive Officer at Quince Therapeutics, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: the appointment of Dirk Thye, M.D. as the Chief Executive Officer of the Company and as principal executive officer and a Class II director of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1662774/000119312522148822/0001193125-22-148822-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.